Schroder Investment Management Group’s Janux Therapeutics JANX Stock Holding History

Schroder Investment Management Group’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-195,160	Closed	-$2.54M	–	1211
2026 Q1	$2.54M	Sell	195,160 -71,891	-27%	-$986K	﹤0.01%	887
2025 Q4	$3.69M	Sell	267,051 -31,827	-11%	-$749K	﹤0.01%	804
2025 Q3	$7.08M	Buy	298,878 +51,962	+21%	+$1.27M	0.01%	720
2025 Q2	$5.7M	Buy	246,916 +54,544	+28%	+$1.44M	﹤0.01%	744
2025 Q1	$5.6M	Buy	192,372 +35,498	+23%	+$1.34M	0.01%	742
2024 Q4	$8.24M	Buy	156,874 +82,601	+111%	+$4.37M	0.01%	684
2024 Q3	$3.44M	Buy	74,273 +39,092	+111%	+$1.7M	﹤0.01%	861
2024 Q2	$1.47M	Buy	+35,181	New	+$1.65M	﹤0.01%	973

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Schroder Investment Management Group's JANX Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 195,160 shares — an estimated $2.54M sold.

Schroder Investment Management Group first reported a position in JANX in Q2 2024 and held it in 8 quarters. The position peaked at $8.24M in Q4 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Schroder Investment Management Group reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
Schroder Investment Management Group sold 195,160 Janux Therapeutics shares in Q2 2026, an estimated $2.54M.
Schroder Investment Management Group first reported a position in Janux Therapeutics in Q2 2024 and held it in 8 quarters.
Schroder Investment Management Group's Janux Therapeutics position peaked at $8.24M in Q4 2024.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.